CompanyHealthAi
Brenig Therapeutics
Brenig Therapeutics is a neurology-focused biotechnology company building disease-modifying small-molecule therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2021 and backed by $65 million in Series A funding led by NEA, Brenig pairs AI- and machine-learning-driven discovery with structure-based design to engineer brain-penetrant molecules that hit the central nervous system while sparing the rest of the body. Its lead candidate, BT-267, is a selective LRRK2 inhibitor now in human trials, followed by BT-409, a brain-selective NLRP3 inflammasome inhibitor targeting neuroinflammation.
2021Founded
DoverHQ
$65,000,000Series A
parkinsons-diseaseneurodegenerative-diseaseslrrk2-inhibitornlrp3-inhibitorneuroinflammationdrug-development
